Clinical Consult provides expert commentary and insights on designated therapeutic topics.
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
In this program Drs. Atish Choudhury and Bobby Liaw discuss recent updates from ASCO, ASCO GU and AUA meetings on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer (mCSPC) and the importance of patient communication and quality of life while on treatment.
Management of Chemotherapy-Ineligible AML: Beyond HMA Monotherapy
Eytan Stein, MD, discusses the management of chemotherapy-ineligible AML, as well as the effect of venetoclax in combination with HMA as a new therapy.
Therapeutic Decision-Making in the Adjuvant Setting in HR+ Breast Cancer
Best practices for the use of gene profiling assays to guide treatment decisions for patients with early-stage HR-positive breast cancer.
Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA
Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.
Ovarian Cancer: Frontline Therapy
Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.
Impact of COVID-19 on the Management of Early-Stage Breast Cancer
Anthony Lucci, MD, provides insight on the management of early-stage breast cancer and evolving therapeutic approaches for patients due to the COVID-19 pandemic.
Using PARP Inhibitors in Frontline Maintenance Therapy of Ovarian Cancer
Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.
Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma
BCMA targeting agents such as the antibody-drug conjugate belantamab mafodotin show promise for heavily pretreated patients with relapsed/refractory multiple myeloma
Multiple Myeloma: Targeting BCMA in the Heavily Pretreated Population
The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.
Assessing the Impact of TAILORx on Breast Cancer Management
ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.
2 Clarke Drive Cranbury, NJ 08512